Skip to main content
SpringerLink
Log in

Intersubject responsiveness of high-affinity growth hormone (GH)-binding protein (GHBP) to long-term GH replacement therapy

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

In adult growth hormone deficiency (GHD) syndrome responsiveness to GH replacement therapy is reported to vary considerably. The underlying mechanisms, however, are not well understood. The aim of this study was to investigate which baseline variables determine the reported variable intersubject responsiveness of high-affinity GH-binding protein (GHBP) to GH replacement therapy. In the setting of a double blind study over 12 months with placebo control over the first 6 months, we analyzed the interrelationship between a number of baseline variables, which vary considerably amongst subjects, and the GHBP response to GH replacement in 31 GHD adults (21 males and 10 females). The following variables were investigated: age, gender, duration of GHD, body composition, serum levels of high-affinity GHBP, insulin-like growth factor-1 (IGF-1), and IGF-binding protein-3 (IGFBP-3). The results showed that in the 6 months treated group of 16 patients (11 males, 5 females), serum IGF-1 increased from 87 ng/ml (range: 26 to 173) to 250 (range: 62 to 467) (p<0.01) and GHBP increased from 1302 pmol/l (range: 845 to 1960) to 1418 (range: 941 to 2025) (p=0.04). Both parameters showed a significant time effect (within-subjects) (p=0.001). In the 12 months treated group of 15 patients (10 males, 5 females), serum IGF-1 increased from 92 ng/ml (range: 20 to 180) to 272 (range: 45 to 491) (p<0.01), whereas GHBP did not show a significant change: from 1186 pmol/l (range: 660 to 1690) to 1252 (range: 580 to 1890) (p=0.87). Also no significant time effect (withinsubjects) was observed for GHBP (p=0.06). Stepwise multiple regression analyses revealed that during the 6 months placebo period baseline GHBP explained 83% of the variance in post-placebo GHBP, whereas the variance in post-treatment GHBP could be accurately predicted (adjusted R2=0.93) from baseline GHBP and body fat mass, irrespective of the duration of GH treatment. No other baseline variables contributed independently to the GHBP response, with the exception of IGFBP-3, which showed a small, but significant contribution in females, but not in males. These findings indicate that the variable intersubject responsiveness of GHBP to GH replacement therapy is mainly due to differences in baseline body fat mass amongst adult GHD patients, and that in female patients a relatively low baseline IGFBP-3 contributes to a rise in serum GHBP after GH treatment. The clinical relevance of measuring GHBP in adult GHD patients is limited to the first screening step to diagnose GHD, because long-term GH therapy tends to restore serum GHBP to pretreatment levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Martha P.M., Reiter E.O., Davila N., Shaw M.A., Holcombe J.H., Baumann G. Serum growth hormone (GH)-binding protein/receptor: an important determinant of GH responsiveness. J. Clin. Endocrinol. Metab. 1993, 75: 1464–1469.

    Google Scholar 

  2. Mandel S., Moreland E., Nichols V., Cheryl H., Lafranchi S. Changes in insulin-like growth factor-1 (IGF-1), IGFbinding protein-3, growth hormone (GH)-binding protein, erythrocyte IGF-1 receptors, and growth rate during GH treatment. J. Clin. Endocrinol. Metab. 1995, 80: 190–194.

    CAS  PubMed  Google Scholar 

  3. Ho K.K.Y., Jórgensen J.O.L., Valiontis E., Waters M.J., Rajkovic I.A., Christiansen J.S. Different modes of growth hormone (GH) administration do not change GH binding protein activity in man. Clin. Endocrinol. 1993, 38: 143–148.

    Article  CAS  Google Scholar 

  4. Davila N., Alcaniz J., Salto L., Estrada J., Barcelo B., Baumann G. Serum growth hormone-binding protein is unchanged in adult panhypopituitarism. J. Clin. Endocrinol. Metab. 1994, 79: 1347–1350.

    CAS  PubMed  Google Scholar 

  5. Postel-Vinay M.-C., Tar A., Hocquette J.-F., Clot J.-P., Fontoura M., Brauner R., Rappaport R. Human plasma growth hormone (GH)-binding proteins are regulated by GH and testosterone. J. Clin. Endocrinol. Metab. 1991, 73: 197–202.

    Article  CAS  PubMed  Google Scholar 

  6. Hochberg Z., Barkey R.J., Even L., Peleg I., Youdim M.B.H., Amit T. The effect of human growth hormone therapy on GH-binding protein in GH-deficient children. Acta Endocrinol. 1991, 125: 23–27.

    CAS  PubMed  Google Scholar 

  7. Tauber M., De Bouet du Portal H., Sallerin-Caute B., Rochiccioli P., Bastide R. Differential regulation of serum growth hormone (GH)-binding protein during continuous infusion versus daily injection of recombinant human GH in GHdeficient children. J. Clin. Endocrinol. Metab. 1993, 76: 1135–1139.

    CAS  PubMed  Google Scholar 

  8. Leger J., Noel M., Czernichow P., Postel-Vinay M.-C. Progressive normalization of growth hormone-binding protein and IGF-1 levels in treated growth hormone-deficient children. Pediatr. Res. 1995, 37: 731–735.

    Article  CAS  PubMed  Google Scholar 

  9. Johannsson G., Bjarnason R., Bramnert M., Carlsson L.M.S., Degerblad M., Manhem P., Rosén T., Thorén M., Bengtsson B.-Å. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age and gender. J. Clin. Endocrinol. Metab. 1996, 81: 1575–1581.

    CAS  PubMed  Google Scholar 

  10. Roelen C.A.M., Koppeschaar H.P.F., de Vries W.R., Snel Y.E.M., Doerga M.E., Zelissen P.M.J., Thijssen J.H.H., Blankenstein M.A. Visceral adipose tissue is associated with circulating high affinity growth hormone-binding protein. J. Clin. Endocrinol. Metab. 1997, 82: 760–764.

    Article  CAS  PubMed  Google Scholar 

  11. Roelen C.A.M., Koppeschaar H.P.F., de Vries W.R., Doerga M.E., Snel Y.E.M., Bol E., Zelissen P.M.J., Thijssen J.H.H., Blankenstein M.A. High-affinity growth hormone (GH)-binding protein (GHBP), body fat mass, and insulin-like growth factor- binding protein-3 predict the GHBP response to GH therapy in adult GH deficiency syndrome. Metab. 1999, 48: 314–318.

    Article  CAS  Google Scholar 

  12. Fisker S., Vahl N., Jörgensen J.O.L., Christiansen J.S., Örskov H. Abdominal fat determines growth hormone-binding protein levels in healthy nonobese adults. J. Clin. Endocrinol. Metab. 1997, 81: 123–128.

    Google Scholar 

  13. Lukaski H.C., Johnson P.E., Bolonchuk W.W., Lykken G.I. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am. J. Clin. Nutr. 1985, 41: 810–817.

    CAS  PubMed  Google Scholar 

  14. Furlanetto R.W., Underwood L.E., Van Wyk J.J., d’Ercole A.J. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J. Clin. Invest. 1977, 60: 648–657.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Davenport M.L., Svoboda M.E., Koerber K.L., Van Wyk J.J., Clemmons D.R. Serum concentrations of insulin-like growth factor-II are not changed by short term fasting and refeeding. J. Clin. Endocrinol. Metab. 1988, 67: 1231–1236.

    Article  CAS  PubMed  Google Scholar 

  16. Roelen C.A.M., Donker G.H., Thijssen J.H.H., Blankenstein M.A. A method for measuring the binding affinity and capacity of high affinity growth hormone binding protein using FPLC to separate bound and free ligand. J. Liquid Chromatogr. 1992, 15: 1259–1275.

    Article  CAS  Google Scholar 

  17. Svensson J., Johannsson G., Bengtsson B.-Å. Insulin-like growth factor-1 in growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test. Clin. Endocrinol. 1997, 46: 579–586.

    Article  CAS  Google Scholar 

  18. Whitehead H.M., Boreham C., McIlrath E.M., Sheridan B., Kennedy L., Atkinson A.B., Hadden D.R. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin. Endocrinol. 1992, 36: 45–52.

    Article  CAS  Google Scholar 

  19. Bengtsson B.-Å., Edén S., Lönn L., Kvist H., Stokland A., Lindstedt G., Bosaeus I., Tölli J., Sjöström L., Isaksson O.G.P. Treatment of adults with growth hormone deficiency with recombinant human growth hormone. J. Clin. Endocrinol. Metab. 1993, 76: 309–317.

    CAS  PubMed  Google Scholar 

  20. Jørgensen J.O.L., Thuesen L., Müller J., Ovesen P., Skakkebaek N.E., Christiansen J.S. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. Eur. J. Endocrinol. 1994, 130: 224–228.

    Article  PubMed  Google Scholar 

  21. De Boer H., Blok G.J., Voerman B., de Vries P., Popp-Snijders C., van der Veen E. The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis. J. Clin. Endocrinol. Metab. 1995, 80: 2069–2076.

    PubMed  Google Scholar 

  22. Johannsson G., Rosén T., Bosaeus I., Sjöström L., Bengtsson B.-Å. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J. Clin. Endocrinol. Metab. 1996, 81: 2865–2873.

    CAS  PubMed  Google Scholar 

  23. Craft W.H., Underwood L.E. Effect of androgens on plasma somatomedin-C/insulinlike growth factor-1 responses to growth hormone. Clin. Endocrinol. 1984, 20: 549–554.

    Article  CAS  Google Scholar 

  24. Liu L., Merriam G.R., Sherins R.J. Chronic sex steroid exposure increases mean plasma growth hormone concentration and pulse amplitude in men with isolated hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 1987, 64: 651–656.

    Article  CAS  PubMed  Google Scholar 

  25. Lieberman S.A., Mitchell A.M., Marcus R., Hintz R.L., Hoffman A.R. The insulin-like growth factor-1 generation test: resistance to growth hormone with aging and estrogen replacement therapy. Horm. Metab. Res. 1994, 26: 229–233.

    Article  CAS  PubMed  Google Scholar 

  26. Dawson-Hughes B., Stern D., Goldman J., Reichlin S. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J. Clin. Endocrinol. Metab. 1986, 63: 424–432.

    Article  CAS  PubMed  Google Scholar 

  27. Kelly J.J., Rajkovic I.A., O’Sullivan A.J., Sernia C., Ho K.K.Y. Effects of differential oral oestrogen formulations on insulin-like growth factor-1, growth hormone and growth hormone binding protein in post-menopausal women. Clin. Endocrinol. 1993, 39: 561–567.

    Article  CAS  Google Scholar 

  28. Massa G., Igout A., Rombauts L., Frankenne F., Vanderschueren-Lodeweyckx M. Effect of oestrogen status on serum levels of growth hormone-binding protein and insulin-like growth factor-1 in non-pregnant and pregnant women. Clin. Endocrinol. 1993, 39: 569–575.

    Article  CAS  Google Scholar 

  29. Veldhuis J.D. Gender differences in secretory activity of the human somatotropic (growth hormone) axis. Eur. J. Endocrinol. 1996, 134: 287–295.

    Article  CAS  PubMed  Google Scholar 

  30. Ulloa-Aguirre A., Blizzard R.M., Garcia-Rubi E., Rogol A.D., Link K., Christie C.M., Johnson M.L., Veldhuis J.D. Testosterone and oxandrolone, a nonaromatizable androgen, specifically amplify the mass and rate of growth hormone (GH) secreted per burst without altering GH secretory burst duration or frequency or the GH half-life. J. Clin. Endocrinol. Metab. 1990, 71: 846–854.

    Article  CAS  PubMed  Google Scholar 

  31. Baumann G., Shaw M.A., Amburn K. Circulating growth hormone binding proteins (review). J. Endocrinol. Invest. 1994, 17: 67–81.

    CAS  PubMed  Google Scholar 

  32. Herington A.C. Growth hormone binding proteins and their relationship to growth hormone receptor (review). Endocrinol. Metab. 1994, 1 (Suppl. A): 9–15.

    Google Scholar 

  33. Baumann G., Amburn K., Buchanan T.A. The effect of circulating growth hormone-binding protein on metabolic clearance, distribution and degradation of human growth hormone. J. Clin. Endocrinol. Metab. 1988, 64: 657–660.

    Article  Google Scholar 

  34. Roelen C.A.M., Koppeschaar H.P.F., de Vries W.R., Zelissen P.M.J, Snel Y.E.M., Doerga M.E., Thijssen J.H.H., Blankenstein R.A. High-affinity growth hormone binding protein, insulin-like growth factor I and insulin-like growth factor binding protein 3 in adults with growth hormone deficiency. Eur. J. Endocrinol. 1996, 135: 82–86.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Physiology and Sports Medicine, University Medical Center Utrecht, Universiteitsweg 100, De Uithof, 3584 CG, Utrecht, The Netherlands

    Wouter R. de Vries M.D., Ph.D. & E. Bol

  2. Department of Endocrinology, University Hospital Utrecht, The Netherlands

    H. P. F. Koppeschaar, C. A. M. Roelen, G. H. Donker, M. E. Doerga & M. Osman-Dualeh

  3. Department of Endocrinology, Pharmacia & Upjohn BV, Woerden, The Netherlands

    Y. E. M. Snel

Authors
  1. Wouter R. de Vries M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. P. F. Koppeschaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Bol
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. A. M. Roelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. H. Donker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. E. Doerga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Osman-Dualeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. E. M. Snel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Vries, W.R., Koppeschaar, H.P.F., Bol, E. et al. Intersubject responsiveness of high-affinity growth hormone (GH)-binding protein (GHBP) to long-term GH replacement therapy. J Endocrinol Invest 23, 449–456 (2000). https://doi.org/10.1007/BF03343754

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343754

Key-words

Search

Navigation